Iceland· IS-EU/1/21/1623/001
Saphnelo
A anifrolumab product containing anifrolumabum inn, registered in Iceland by AstraZeneca AB*. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Anifrolumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG11 (anifrolumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Anifrolumab · ATC L04AG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of anifrolumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Anifrolumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$42.60
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Anifrolumabum INN
- Manufacturer
- AstraZeneca AB*
- Country
- Iceland (IS)
- ATC code
- L04AG11
- ATC class
- Anifrolumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean4690032 ml x1 hglISK 167238
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSaphnelo 300 mgAstraZeneca
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- FinlandSaphneloAstraZeneca AB
- IrelandSaphnelo 300 mg Concentrate for solution for infusionAstraZeneca AB
- NorwaySaphneloAstraZeneca AB (2)
- PolandSaphneloAstraZeneca AB
- SwedenSAPHNELO 300 mg Koncentrat till infusionsvätska, lösningAstraZeneca AB
- SwitzerlandSaphnelo 120 mg/0.8 ml, Injektionslösung in einem FertigpenAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Saphnelo
- Norway · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e69054fc-c44c-45e1-b2d8-a030543b1f8b GET /v1/drugs/e69054fc-c44c-45e1-b2d8-a030543b1f8b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AG11",
"marketed": true,
"strength": "300 mg",
"ma_number": "EU/1/21/1623/001",
"substance": "Anifrolumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44606"
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.